Cover
Document Information [Table]
Entity Addresses, Address Type [Axis]
Address Type [Domain]
Business Contact [Member]
Document Information [Line Items]
Document Type
Document Registration Statement
Document Annual Report
Document Period End Date
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Transition Report
Document Shell Company Report
Entity File Number
Entity Registrant Name
Entity Incorporation, State or Country Code
Contact Personnel Name
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, Postal Zip Code
Entity Address, State or Province
Entity Address, Country
City Area Code
Local Phone Number
Contact Personnel Email Address
Title of 12(b) Security
Trading Symbol
Entity Common Stock, Shares Outstanding
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Emerging Growth Company
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Document Accounting Standard
Entity Shell Company
Auditor Firm ID
Auditor Name
Auditor Location
Entity Central Index Key
Document Fiscal Period Focus
Amendment Flag
Consolidated Balance Sheets
Statement [Table]
Statement [Line Items]
Statement
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
Current assets:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Amount of investment in equity security measured at fair value.
Investment Equity Securities, Fair Value
Investment in equity securities, at fair value
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable, net
Accounts receivable, net of nil expected credit loss
Inventory, Net
Inventories
Total
Prepaid Expense and Other Assets, Current
Prepaid expenses and other
Assets, Current
Total current assets
Long-term Investments
Long-term investments
Property, Plant and Equipment, Net
Property, plant and equipment, net
Property, plant and equipment, net
Intangible Assets, Net (Excluding Goodwill)
Intangible assets, net
Operating Lease, Right-of-Use Asset
Right of use assets
Other Assets, Noncurrent
Other assets
Assets
Total assets
Liabilities and Equity [Abstract]
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities, Current [Abstract]
Current liabilities:
Accounts Payable, Current
Accounts payable
Short-Term Bank Loans and Notes Payable
Bank borrowings
Accrued And Other Liabilities, Current
Accrued and other current liabilities
Accrued and other current liabilities
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
Convertible Notes Current
Convertible notes due to a related party
Long-term Debt, Current Maturities
Current portion of long term borrowing
Liabilities, Current
Total current liabilities
Other Liabilities, Noncurrent
Other Liabilities
Other liabilities
Liabilities
Total liabilities
Commitments and Contingencies.
Commitments and contingencies (Note 19)
Stockholders' Equity Attributable to Parent [Abstract]
Shareholders' (deficit) equity:
Common Stock, Value, Issued
$0.0001 par value, 500,000,000 shares authorized 20,967,869 shares and 15,904,533 shares issued at December 31, 2025 and 2024, respectively; 20,555,873 shares and 15,492,581 shares outstanding at December 31, 2025 and 2024, respectively
Ordinary shares
Treasury Stock, Value
Treasury shares, at cost: 411,996 shares and 411,952 shares held at December 31, 2025 and 2024
Treasury shares
Additional Paid in Capital
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Stockholders' Equity Attributable to Parent
Balance
Balance
Total shareholders' (deficit) equity
Liabilities and Equity
Total liabilities and shareholders' (deficit) equity
Total liabilities and shareholders' (deficit) equity
Accounts Receivable, Allowance for Credit Loss, Current
Accounts receivable, expected credit loss
Common Stock, Par or Stated Value Per Share
Common stock par value (in dollars per share)
Common Stock, Par Value (in dollars per share)
Common Stock, Shares Authorized
Authorized common stock (in shares)
Common Stock, Shares, Issued
Common Stock, Shares Issued (in shares)
Common Stock, Shares Outstanding
Common Stock, Shares Outstanding (in shares)
Treasury Stock, Common, Shares
Treasury stock, Shares Held (in shares)
Common stock in treasury (in shares)
Consolidated Statements of Operations and Comprehensive Loss
Revenues
Revenues
Revenues
Cost of Goods and Services Sold
Costs of revenues
Costs of revenues
Gross Profit
Gross Profit
Costs and Expenses [Abstract]
Operating expenses:
Operating (expenses) income:
Research and Development Expense.
Research and development
General and Administrative Expense.
General and administrative
Selling and Marketing Expense
Selling and marketing
Other Operating Income
Other operating income
Gain (Loss) on Disposition of Assets
Gain on disposal of long-lived assets
Foreign Currency Transaction Gain (Loss), before Tax
Foreign exchange gain (loss)
Impairment of Intangible Assets, Finite-lived
Impairment
Impairment of intangible assets
Impairment of intangible assets
Costs and Expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Nonoperating Income (Expense) [Abstract]
Non-operating (expense) income:
Interest Income (Expense), Net
Interest expense
Interest Income, Operating and Nonoperating
Interest income
Other Nonoperating Income (Expense)
Other income
Other non-operating income (expenses)
Equity Securities, FV-NI, Gain (Loss)
Change in fair value of investments
Change in fair value of investments
Debt and Equity Securities, Realized Gain (Loss)
Impairment loss of long-term investments
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss before income tax benefit and share of net loss in an equity investee
Income Tax Expense (Benefit)
Income tax benefit
Income tax expense
Total
Amount of income (loss) from continuing operations, attributable to noncontrolling interest, and addition of income (loss) from equity method investments net of tax.
Income (Loss) from Continuing Operations before Equity Method Investments, Noncontrolling Interest, After Tax
Net loss before share of net loss in an equity investee
Income (Loss) from Equity Method Investments
Share of net loss of an equity investee
Share of net loss in an equity investee
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net loss
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
Less:Loss attributable to redeemable noncontrolling interest
Share of CASI Wuxi net loss
Amount of decrease to net income for accretion of redeemable noncontrolling interest to its redemption value to derive net income apportioned to common stockholders.
Redeemable Noncontrolling Interest, Accretion To Redemption Value, Adjustment
Accretion to redeemable noncontrolling interest redemption value
Amount of deemed dividend to subsidiary recognized from the difference between the present value of the Exchanged Liabilities and the carrying amount of the redeemable noncontrolling interest.
Deemed Dividends Adjustment
Deemed dividends to Wuxi LP
Deemed Dividends Adjustment
Net loss attributable to CASI Pharmaceuticals, Inc.
Net loss
Earnings Per Share, Basic
Net loss per share (basic) (in $ per share)
Earnings Per Share, Diluted
Net loss per share (diluted) (in $ per share)
Weighted Average Number of Shares Outstanding, Basic
Weighted average number of ordinary shares outstanding (basic)
Weighted Average Number of Shares Outstanding, Diluted
Denominator for basic and diluted net loss per share calculation
Weighted average number of ordinary stock outstanding (diluted)
Statement of Comprehensive Income [Abstract]
Comprehensive loss:
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent
Foreign currency translation adjustment
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Total comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
Less: Comprehensive loss attributable to redeemable noncontrolling interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss attributable to ordinary shareholders
Consolidated Statements of Stockholders' Equity
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Common Stock
Additional Paid-in Capital [Member]
Additional Paid-in Capital
Treasury Stock [Member]
Treasury Stock
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss)
Retained Earnings [Member]
Accumulated Deficit
Sale of Stock [Axis]
Sale of Stock [Domain]
Represents information pertaining to July 2024 PIPE transaction.
July 2024 Private Investment in Public Equity Financing [Member]
2024 PIPE transaction
Information related to Open Market Sale Agreement.
Open Market Sale Agreement [Member]
Open Market Sale Agreement
Shares, Outstanding
Balance (in shares)
Balance (in shares)
Value of stock issued as a result of the exercise of stock options and warrants.
Stock Issued During Period, Value, Stock Options And Warrants Exercised
Issuance of ordinary shares for options and warrants exercised
Number of share options (or share units) and warrants exercised during the current period.
Stock Issued During Period, Shares, Stock Options And Warrants Exercised
Issuance of ordinary shares for options and warrants exercised (in shares)
Stock Repurchased and Retired During Period, Value
Repurchase of ordinary shares
Repurchase and retirement of common stock
Stock Repurchased and Retired During Period, Shares
Repurchase of ordinary shares (in shares)
Repurchase and retirement stock (in shares)
Stock Issued During Period, Value, Stock Options Exercised
Issuance of ordinary shares for options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Exercised (in shares)
Issuance of ordinary shares for options exercised (in shares)
Stock Issued During Period, Value, New Issues
Issuance of ordinary share pursuant to a PIPE Transaction
Proceeds from sale of ordinary shares
Stock Issued During Period, Shares, New Issues
Shares issued
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Share issuance costs of a PIPE or ATM Transaction (Note 12)
Amount of increase (decrease) in additional paid in capital (APIC) resulting from issuance of convertible notes.
Adjustments to Additional Paid in Capital, Issuance Of Convertible Notes
Deemed contribution from shareholder as a result of issuance of Convertible notes (Note 18)
Deemed contribution from shareholder as a result of issuance of Convertible notes
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Share-based compensation expense, net of forfeitures
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Fair value change of available for sale debt security
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax
Available for sale debt security reclassification adjustment
Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax
Foreign currency translation adjustment
Consolidated Statements of Cash Flows
Counterparty Name [Axis]
Counterparty Name [Domain]
Information related to Black Belt Therapeutics Limited.
Black Belt Tx Limited [Member]
Black Belt Tx Limited
Represents information pertaining to Cleave Therapeutics, Inc.
Cleave Therapeutics Inc [Member]
Cleave Therapeutics, Inc
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Depreciation for property, plant and equipment
The aggregate expense charged against earnings to allocate the cost of intangible assets and assets held for sale.
Amortization Of Intangible Assets And Held For Sale
Amortization of intangible assets
This represents reduction in the carrying amount of the right-of-use assets.
Reduction in the Carrying Amount of the Right-of-Use Assets
Reduction in the carrying amount of the right-of-use assets
Gain (Loss) on Disposition of Intangible Assets
(Gain) loss on disposal of long-lived assets
Inventory write down
Write down of obsolete inventories
Write-down of inventories
Share-based Compensation.
Share-based compensation expense
Debt Securities, Realized Gain (Loss)
Gain from extinguishment of investment in a convertible loan
Gain from extinguishment of investment in a convertible loan
Amount of impairment loss of long-term investments.
Impairment Loss of Long-term Investments
Impairment loss of long-term investments
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable
Accounts receivable
Increase (Decrease) in Due from Related Parties, Current
Receivable from a related party
Increase (Decrease) in Inventories
Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other
Increase (Decrease) in Accounts Payable, Trade
Accounts payable
Increase (Decrease) in Accrued Liabilities
Accrued liabilities and other liabilities
Increase (Decrease) in Income Taxes Payable
Income tax payable
Net Cash Provided by (Used in) Operating Activities
Net cash provided by (used in) operating activities
Net cash used in operating activities
Cash outflow for operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES
Payments to Acquire Property, Plant, and Equipment
Purchases of property, plant and equipment
Proceeds from Sale of Intangible Assets
Proceeds from sale of intangible assets
Proceeds from sale of intangible assets
Payments to Acquire Intangible Assets
Purchase of intangible assets
Purchases of intangible asset
Proceeds from Sale of Equity Securities, FV-NI
Proceeds from sales of equity securities
Payments to Acquire Equity Method Investments
Cash paid to acquire equity interests in an equity method investee
Payments to acquire equity investments
The amount of cash outflow associated with purchase of short term investments and term deposits.
Purchase of Short Term Investments and Term Deposits
Purchase of short term investments and term deposits
The amount of cash inflow associated with proceeds from sales or maturity of short term investments and term deposits.
Proceeds from Sales or Maturity of Short Term Investments and Term Deposits
Proceeds from sales or maturity of short term investments and term deposits
Represents the information pertaining to government grant received from Jiangsu Province Wuxi Huishan Economic Development Zone for development project.
Proceeds from Government Grant
Government grant received
Receipt from government for return of Wuxi land use right
The amount of proceeds from extinguishment of investment in a convertible loan.
Proceeds from Extinguishment of Investment in a Convertible Loan
Proceeds from extinguishment of investment in a convertible loan
Net Cash Provided by (Used in) Investing Activities
Net cash provided by (used in) investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES
The cash inflow from the additional capital contribution to the entity through the issuance of common stock and warrants.
Proceeds from Issuance of Common Stock and Warrants
Proceeds from issuance of ordinary share
Proceeds from issuance of ordinary shares
Payments of Stock Issuance Costs
Payment of issuance costs
Payment of share issuance costs
Proceeds from Convertible Debt
Proceeds from issuance of convertible note
Proceeds from issuance of convertible notes
Proceeds from Stock Options Exercised
Proceeds from exercise of share options
Payments of Ordinary Dividends, Noncontrolling Interest
Dividend payment to Wuxi LP
Proceeds from Lines of Credit
Proceeds from bank borrowings
Payments for Repurchase of Common Stock
Repurchase of ordinary shares
Repurchase of ordinary share
Net Cash Provided by (Used in) Financing Activities
Net cash provided by (used in) financing activities
Effect of Exchange Rate on Cash and Cash Equivalents
Effect of exchange rate change on cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Cash and cash equivalents at end of year
Cash and cash equivalents at beginning of year
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Interest paid
Income Taxes Paid, Net
Income taxes paid
Noncash Investing and Financing Items [Abstract]
Non-cash investing and financing activities:
Capital Expenditures Incurred but Not yet Paid
Payables related to property, plant and equipment
Debt Conversion, Converted Instrument, Amount
Exchange of redeemable noncontrolling interest to long term borrowing (Note 11)
DESCRIPTION OF BUSINESS
Basis of Accounting [Text Block]
DESCRIPTION OF BUSINESS
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Significant Accounting Policies [Text Block]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS
Investment Holdings, Schedule of Investments [Text Block]
INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS
INVENTORIES
Inventory Disclosure [Text Block]
INVENTORIES
LEASES
Leases of Lessee Disclosure [Text Block]
LEASES
PROPERTY, PLANT AND EQUIPMENT
Property, Plant and Equipment Disclosure [Text Block]
PROPERTY, PLANT AND EQUIPMENT
INTANGIBLE ASSETS
Intangible Assets Disclosure [Text Block]
INTANGIBLE ASSETS
ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES
The entire disclosure for accrued and other current liabilities and other liabilities.
Accrued and Other Current Liabilities and Other Liabilities Disclosure [Text Block]
ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES
SHORT TERM BORROWINGS
Short-Term Debt [Text Block]
SHORT TERM BORROWINGS
Grants, Disclosure [Abstract]
GRANTS
The entire disclosure for grants receivable or received by the company.
Grants, Disclosure [Text Block]
GRANTS
No definition available.
REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING
Entire disclosure of redeemable non controlling interest and long term borrowing.
Redeemable Non controlling Interest and Long Term Borrowing [Text Block]
REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING
SHAREHOLDERS' (DEFICIT) EQUITY
Stockholders' Equity Note Disclosure [Text Block]
SHAREHOLDERS' (DEFICIT) EQUITY
NET LOSS PER SHARE
Earnings Per Share [Text Block]
NET LOSS PER SHARE
EMPLOYEE BENEFIT PLAN
Compensation and Employee Benefit Plans [Text Block]
EMPLOYEE BENEFIT PLAN
SHARE-BASED COMPENSATION
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
SHARE-BASED COMPENSATION
INCOME TAXES
Income Tax Disclosure [Text Block]
INCOME TAXES
FAIR VALUE MEASUREMENTS
Fair Value Disclosures [Text Block]
FAIR VALUE MEASUREMENTS
RELATED PARTY TRANSACTIONS
Related Party Transactions Disclosure [Text Block]
RELATED PARTY TRANSACTIONS
COMMITMENTS AND CONTINGENCIES
Commitments and Contingencies Disclosure [Text Block]
COMMITMENTS AND CONTINGENCIES
No definition available.
RESTRICTED NET ASSETS
The entire disclosure for restricted net assets.
Restricted Net Assets [Text Block]
RESTRICTED NET ASSETS
SUBSEQUENT EVENTS
Subsequent Events [Text Block]
SUBSEQUENT EVENTS
CONDENSED FINANCIAL INFORMATION OF REGISTRANT
Condensed Financial Information of Parent Company Only Disclosure [Text Block]
CONDENSED FINANCIAL INFORMATION OF REGISTRANT
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Consolidation, Policy [Policy Text Block]
Consolidation
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency Translation and Transactions
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations Risks
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Credit Loss, Financial Instrument [Policy Text Block]
Allowance for Credit Losses
Inventory, Policy [Policy Text Block]
Inventories
Accounts Receivable [Policy Text Block]
Prepaid expenses and other
Research and Development Expense, Policy [Policy Text Block]
Research and Development Expenses
Property, Plant and Equipment, Policy [Policy Text Block]
Property, Plant and Equipment
Cost of Goods and Service [Policy Text Block]
Costs of Revenues
Investment, Policy [Policy Text Block]
Investments
Lessee, Leases [Policy Text Block]
Leases
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
In Process Research and Development, Policy [Policy Text Block]
Acquired In-Process Research and Development Expense
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Share-Based Compensation
Disclosure of accounting policy for government grants.
Government Grants [Policy Text Block]
Government Grants
Income Tax, Policy [Policy Text Block]
Income Taxes
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Pronouncements
Investment Holdings, Schedule of Investments [Table Text Block]
Schedule of investments in equity securities
Tabular disclosure for long term investments.
Schedule Of Long Term Investments [Table Text Block]
Schedule of components of long-term investments
Schedule of Inventory, Current [Table Text Block]
Schedule of inventories
Tabular disclosure of operating lease related assets and liabilities and other related information.
Disclosure of Lease on Consolidated Balance Sheet [Table Text Block]
Schedule of right of use assets and liabilities on condensed balance sheet
Tabular disclosure of operating lease related cash flow information.
Disclosure of Supplemental cash flow information related to leases [Table Text Block]
Schedule of supplemental cash flow information
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Schedule of future undiscounted cash flows
Property, Plant and Equipment [Table Text Block]
Schedule of property, plant and equipment
Finite-lived Intangible Assets Amortization Expense [Table Text Block]
Schedule of net definite-lived intangible assets
Schedule of Finite-Lived Intangible Assets [Table Text Block]
Schedule of changes in intangible assets
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Schedule of expected future amortization expense
Tabular disclosure of accrued and other current liabilities and other liabilities.
Schedule of Accrued and Other Current Liabilities and Other Liabilities [Table Text Block]
Schedule of accrued and other current liabilities and other liabilities
Redeemable Noncontrolling Interest [Table Text Block]
Schedule of changes in redeemable noncontrolling interest
Tabular disclosure related to the share based warrant activity.
Schedule Of Warrant Activity [Table Text Block]
Schedule of share purchase warrants activity
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of basic and diluted net loss per share
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Schedule of compensation expense
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of weighted-average assumptions used in valuing the stock options
Share-based Compensation, Stock Options, Activity [Table Text Block]
Schedule of stock option plans and of changes in options outstanding under the plans
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
Schedule of stock options outstanding
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Schedule of domestic and foreign loss before income taxes
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of deferred income tax assets and liabilities
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of reconciliation of provision for income taxes to the federal statutory rate
Summary of Valuation Allowance [Table Text Block]
Schedule of valuation allowance
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Schedule of reconciliation of gross unrecognized tax benefits
Fair Value, Recurring and Nonrecurring [Table]
Measurement Frequency [Axis]
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of financial assets and liabilities accounted for at fair value on a recurring basis
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of quantitative information about level 3 fair value measurements
Condensed Balance Sheet [Table Text Block]
Schedule of Condensed Balance Sheets
Condensed Income Statement [Table Text Block]
Schedule of Condensed Statements of Operations and Comprehensive Loss
Condensed Cash Flow Statement [Table Text Block]
Schedule of Condensed Statements of Cash Flows
No definition available.
Schedule of Description of Business and Basis of Presentation [Table]
Legal Entity [Axis]
Entity [Domain]
Information related to CASI China.
Casi China [Member]
CASI China
CASI China & Hongkong
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Represents the information pertaining to FOLOTYN.
FOLOTYN [Member]
License of FOLOTYN
FOLOTYN
Type of Arrangement and Non-arrangement Transactions [Axis]
Arrangements and Non-arrangement Transactions [Domain]
Represents the information pertaining to Mundipharma International Corporation Limited license agreement.
License Agreement with Mundipharma International Corporation Limited [Member]
License Agreement with Mundipharma International Corporation Limited
Disposal Group Classification [Axis]
Disposal Group Classification [Domain]
Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Held-for-Sale or Disposed of by sale, not discontinued operations
Represents the information pertaining to Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals").
Kaixin Pharmaceuticals Inc [Member]
Kaixin Pharmaceuticals Inc
Represents the information pertaining to Dr. Wei-Wu He, one of the Company's board of directors
Dr. Wei Wu He [Member]
Dr. Wei Wu He
Disposal Group Name [Axis]
Disposal Group Name [Domain]
Represents the information pertaining to target companies being BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan).
Target Companies [Member]
Target companies
Related Party [Axis]
Related Party [Domain]
Related Party [Member]
Related Party
Title of Individual [Axis]
Relationship to Entity [Domain]
Director [Member]
Director
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Events
Subsequent event
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Represents the information pertaining to convertible loan.
Convertible Loan [Member]
Convertible loan
Investment, Name [Axis]
Investment, Name [Domain]
Represents the information pertaining to the Precision Autoimmune Therapeutics Co., Ltd., ("PAT").
Precision Autoimmune Therapeutics Co. Ltd [Member]
Precision Autoimmune Therapeutics Co., Ltd
Range [Axis]
Range [Domain]
Minimum [Member]
Minimum
n/a.
Description of Business and Basis of Presentation [Line Items]
Description of Business and Basis of Presentation
Represents the number of wholly owned subsidaries.
Number of Wholly Owned Subsidiaries
Number of wholly owned subsidiaries
The percentage of ownership in Disposal Group.
Disposal Group, Ownership Percentage
Disposal group, ownership percentage
Disposal Group, Including Discontinued Operation, Consideration
Disposal group, including discontinued operation, consideration
Disposal Group, Including Discontinued Operation, Liabilities
Liabilities of disposal group including discontinued operation
Per share amount proposed to be purchase.
Proposed Purchase Price Per Share
Proposed purchase price per share
Percentage of premium to the average closing price.
Premium Percentage Over Average Closing Price
Premium percentage over average closing price
Threshold period of specified consecutive trading days within which average closing price of ordinary share is computed.
Threshold Consecutive Tradings Days For Computing Average Closing Price
Threshold consecutive tradings days for computing average closing price
The number of investors.
Number Of Investors
Number of investors
The amount of investment principal returned.
Investment Principal Returned
Investment principal returned
The amount of investment principal made by the entity.
Investment Principal
Investment principal
Debt Instrument, Term
Term of loan (in years)
Loan term
Debt Instrument, Interest Rate, Stated Percentage
Interest rate (as a percent)
Term of anniversary after the maturity of loan.
Term of Anniversary After the Maturity of Loan
Loan, conversion term (in years)
Amount represent the surplus of a company's current assets over its current liabilities.
Current Assets, Net
Current assets, net
Equity Method Investment, Ownership Percentage
Equity ownership (as a percent)
The amount of aggregate consideration for equity investment.
Aggregate Consideration For Equity Investment
Aggregate consideration for equity investment
Equity investment amount
Total number of installments in which the consideration for equity method investment will be paid.
Equity Method Investment, Aggregate Number Of Installments
Number of installments
The amount payable under the license agreement.
License Agreement, Amount Payable
License agreement, amount payable
The amount of one time payment payable upon completion of quality audit under the license agreement.
License Agreement, One Time Payment, Payable Upon Completion of Quality Audit
License agreement, one time payment, payable upon completion of quality audit
Sublicensing revenue from a related party.
Sublicensing Revenue From Related Party
Sublicensing revenue from a related party
Percentage of net sales.
Percentage of Net Sales
Percentage of net sales
The aggregate amount payable in quarterly installments under the license agreement.
License Agreement, Aggregate Amount Payable in Quarterly Installment
License agreement, aggregate amount payable in quarterly installment
Represents the amount payable becomes due immediately upon event of non payment of one time payment payable upon completion of quality and quarterly installments under the license agreement.
License Agreement, Amount Payable on Completion of Audit and Deferred Quarterly Payments Becomes Due Immediately Upon Event of Non Payment
License agreement, amount payable on completion of audit and deferred quarterly payments becomes due immediately upon event of non payment
Information related to China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. ("CRPCGIT").
China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. [Member]
China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.
Information related to China National Medicines Corporation Ltd.
China National Medicines Corporation Ltd. [Member]
China National Medicines Corporation Ltd.
Represents the information pertaining to Exclusive Distribution Agreement.
Exclusive Distribution Agreement [Member]
Exclusive Distribution Agreement
The period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Non Royalty Exclusive Distribution Period
Non royalty exclusive distribution period (in years)
The additional period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Non Royalty Exclusive Distribution Additional Period
Non royalty exclusive distribution additional period (in years)
Agreement extension
Term of Agreement.
Term of Agreement
Term of agreement (in years)
Information related to Guangzhou Gloria Biosciences Co., Ltd.
Guangzhou Gloria Biosciences Co., Ltd. [Member]
Guangzhou Gloria Biosciences Co., Ltd.
The amount of upfront payment.
Upfront Payment
Upfront payment
Number of installments for upfront payment.
Number Of Installments For Upfront Payment
Number of installments for upfront payment
Information related to Juventas Cell Therapy Ltd.
Juventas Cell Therapy Ltd [Member]
Juventas Cell Therapy Ltd.
The amount of milestone payment under license agreement.
License Agreement, Milestone Payment
Milestone payment
Stockholders' Equity Attributable to Noncontrolling Interest
Equity attributable to noncontrolling interest
The maximum value of entity assets freezed.
Maximum Value of Entity Assets Freezed
Entity assets freezed
Information related to BioInvent International AB.
Bioinvent International Ab [Member]
BioInvent International AB
Maximum [Member]
Maximum
The potential milestone and royalty payment.
Potential Milestone Payment And Royalty
Potential milestones and royalties
The amounts of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.
Research And Development In Process 1
Acquired in-process research and development
Number of shares invested under equity method investment.
Equity Method Investment, Shares
Number of new shares issued
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants issued
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Each warrants issued for new share
Period for subscription of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Subscription Period For Warrants
Subscription period for warrants (in years)
Share Price
Offering price per share
Exercise price
Equity Method Investments
Investment
Information related to Black Belt Therapeutics Limited ("Black Belt").
Black Belt Therapeutics Limited [Member]
Black Belt Therapeutics Ltd
Research and Development Asset Acquired Other than Through Business Combination, Written-off
In-process research and development expensed
Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]
The amount of development milestone payment payment payable under the license agreement.
License Agreement, Development Milestone Payment Payable
Development milestone payable
The amount of sales milestone payment payment payable under the license agreemen
License Agreement, Sales Milestone Payment Payable
Sales milestone payable
Represents the information pertaining to Assignment Agreement with Cleave.
Assignment Agreement with Cleave [Member]
Assignment Agreement with Cleave
Extinguishment of Debt, Amount
Repayment of debt
Principal amount
The amount of commercial and sales milestone payments payable under the assignment agreement.
Assignment Agreement, Commercial and Sales Milestone Payments Payable
Assignment agreement, commercial and sales milestone payments payable
Percentage of royalty on net sales payable under the assignment agreement.
Assignment Agreement, Percentage of Royalty on Net Sales Payable
Assignment agreement, percentage of royalty on net sales payable
Information related to Pharmathen Global BV.
Pharmathen Global Bv [Member]
Pharmathen Global BV
Income Statement Location [Axis]
Income Statement Location [Domain]
Other Operating Income (Expense) [Member]
Other income
Other operating income
Amount of additional milestone payments.
Additional Milestone Payments
Additional milestone payments
The amount of refund received from termination of license agreement
License Agreement, Refund from Termination of Agreement
License agreement refunded
Number of Reportable Segments
Number of reportable segments
Concentration Risk [Table]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Domain]
Revenue Benchmark [Member]
Revenues
Accounts Receivable [Member]
Accounts receivable
Concentration Risk Type [Axis]
Concentration Risk Type [Domain]
Customer Concentration Risk [Member]
Customer concentration
Customer [Axis]
Customer [Domain]
Concentration Risk [Line Items]
Number of major suppliers, where each supplier accounting over 10% of supplies.
Number Of Major Suppliers
Number of major suppliers
Concentration Risk, Percentage
Concentration risk percentage
Schedule of Cash and Cash Equivalents [Table]
Geographical [Axis]
Geographical [Domain]
CHINA
CHINA
China
HONG KONG
HONG KONG
Hong Kong
UNITED STATES
UNITED STATES
United States
Cash and Cash Equivalents [Line Items]
Cash and Cash Equivalents
Value Added Tax Receivable
Deductible Value Added Tax ("VAT")
Property, Plant and Equipment [Table]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset [Domain]
Represents information related to furniture and equipment.
Furniture And Equipment [Member]
Office equipment and furniture
Represents information related to machinery and lab equipment.
Machinery And Lab Equipment [Member]
Machinery and lab equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment
Property, Plant and Equipment, Useful Life
Estimated useful life
Schedule of Investments [Table]
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Measurement Input, Price Volatility [Member]
Expected volatility
Measurement Input, Risk Free Interest Rate [Member]
Risk Free Interest Rate
Schedule of Investments [Line Items]
Schedule of Investments
Equity Method Investment, Investment To Be Made
Investment to be made
Investment to be made
Number of shares subscribed by the company.
Number Of Shares To Be Subscribed
Number of shares subscribed (in shares)
Number of warrants to be subscribed by the company.
Number Of New Warrants Subscribed
Number of new warrants subscribed (in shares)
Number Of Warrants Subscribed Per Share Ratio.
Number Of Warrants Subscribed Per Share
Number of shares subscribed per warrant (in shares)
Fair Value Adjustment of Warrants
Fair value of the warrants
Warrants and Rights Outstanding, Term
Warrants expected life (in years)
Warrants and Rights Outstanding, Measurement Input
Warrants , Measurement Input
The increase (decrease), resulting in a loss, that was included in earnings for the period.
Unrealized Loss
Unrealized losses
The increase (decrease), resulting in a gain, that was included in earnings for the period.
Unrealized Gains
Unrealized gains
Sale of Stock, Number of Shares Issued in Transaction
Number of ordinary shares sold (in shares)
Equity Securities, FV-NI, Realized Gain (Loss)
Recognized (losses) or gains
Warrant [Member]
Warrants
Available-for-sale Equity Securities, Amortized Cost Basis
Cost
Equity Securities, FV-NI, Unrealized Gain (Loss)
Gross unrealized losses
Investments, Fair Value Disclosure
Equity securities at fair value
Schedule of information pertaining to long term investments.
Schedule Of Long Term Investments [Table]
Represents information relating to Alesta Tx.
Alesta Tx [Member]
Alesta Tx
Financial Instrument [Axis]
Financial Instruments [Domain]
Preferred Stock [Member]
Preferred Stock
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Schedule Of Long Term Investments [Line Items]
Schedule Of Long Term Investments
Debt Securities, Trading, and Equity Securities, FV-NI, Cost
Cost
Amount of unrealized gain (loss) on investment in debt and equity securities including impairment charges.
Debt and Equity Securities, Unrealized Gain (Loss) Including Impairment
Gross unrealized losses (including impairment)
Debt Securities, Trading
Carrying amount
Investment, Type [Extensible Enumeration]
Class of Stock [Axis]
Class of Stock [Domain]
Series A Preferred Stock [Member]
Series A Preferred Shares
The percentage of ownership of common stock or equity participation in the investee.
Ownership Percentage
Equity ownership (as a percent)
Amount of equity method investments contribution.
Equity Method Investments Contribution
Contribution amount
Number of shares issued upon exchange.
Equity Method Investments Exchange of Common Stocks
Exchange of common stocks
Percentage of the fully diluted capital.
Fully Diluted Capital Percentage
Percentage of fully diluted capital
Equity Method Investment, Other than Temporary Impairment
Impairment of equity investment
The maximum amount that can be borrowed by the related party borrower under the loans advanced by the company.
Loan To Be Advanced
Loan to be advanced
Related Party Transaction, Rate
Interest rate (as a percent)
Amount of equal installments in which loan will be advanced to related party.
Loans Advanced To Related Party, Amount Of Equal Installments
Convertible loan tranches repaid
Percentage of price per share issued at which outstanding principal loan advanced to related party is to be converted.
Loans Advanced To Related Party, Percentage Of Price Per Share Issued At Which Outstanding Principal Loan Is To Be Converted
Percentage of price per share issued at which the outstanding principal loan is to be converted
Debt Conversion, Converted Instrument, Shares Issued
Shares conversion
Debt Instrument, Convertible, Conversion Price
Conversion price
Equity Securities without Readily Determinable Fair Value, Amount
Investment in equity securities using measurement alternative, fair value
Amount of gain (loss) on difference between the fair values of shares issued and the fair value of the convertible debt.
Debt Securities Conversion, Gain (Loss) On Fair Value
Debt securities conversion, gain (loss) on fair value
The amount of investment in convertible note.
Investment in Convertible Note
Investment in convertible note
Term of the loan advanced to related party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Loans Advanced To Related Party, Term
Term of loan provided
Minimum amount of equity financing round to be completed by the borrower, to trigger the conversion of loans advanced by the company.
Loans Advanced To Related Party, Conversion, Minimum Equity Financing Round Amount
Minimum equity financing round amount
Percentage of per share price at which the loans advanced to related party shall be converted into shares by the company.
Loans Advanced To Related Party, Conversion, Percentage Of Per Share Price
Percentage of per share price at which the loans advanced will be converted
Assets, Fair Value Adjustment
Change in fair value of investment in equity securities
Represents information relating to agreement one.
Agreement One [Member]
Agreement one
Represents information relating to agreement two.
Agreement Two [Member]
Agreement Two
Represents the percentage of equity held in joint venture.
Percentage of Equity Held in Joint Venture
Percentage of equity held in joint venture
Represents percentage of interest in board seats.
Percentage of Interest in Board Seats
Percentage of interest in board seats
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting obtained during the period.
Equity Method Investment, Ownership Percentage, Acquired During The Period
Equity method investment, ownership percentage
Inventory, Current [Table]
Inventory [Line Items]
Inventory, Finished Goods, Net of Reserves
Finished goods
Inventory, Work in Process, Net of Reserves
Work in progress
Inventory, Raw Materials, Net of Reserves
Raw materials
Lessor, Lease, Description [Table]
Information related to CASI Wuxi.
CASI Wuxi [Member]
CASI Wuxi
Lease Contractual Term [Axis]
Lease Contractual Term [Domain]
Represents information relating to office space lease.
Office Space Lease
Office Space Lease
Lessor, Lease, Description [Line Items]
Lessor, Operating Lease, Term of Contract
Term of lease contract
The number of operating leases.
Number of Operating Leases
Number of operating lease
Operating Lease, Weighted Average Remaining Lease Term
Weighted average remaining lease term
Operating Lease, Weighted Average Discount Rate, Percent
Weighted average discount rates
Variable Lease, Cost
Variable lease costs
Operating Lease, Cost
Rent expenses
Operating Lease, Liability, Current
Lease liabilities, current
Lease liabilities-current (Note 5)
Amounts due within 12 months
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Noncurrent
Lease liabilities-noncurrent (Note 5)
Non-current lease liability
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]
Operating Lease, Liability
Total lease liabilities
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Cash paid for amounts included in the measurement of lease liabilities:
Operating Lease, Payments
Operating cash flows
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Right of use assets obtained in exchange for lease obligations
The amount right of use assets remeasured.
Right of Use Assets Remeasured
Increase of right of use assets from remeasurement
Operating Leases, Future Minimum Payments Receivable, Current
2026
Lessee, Operating Lease, Liability, Payments, Due Year Two
2027
Lessee, Operating Lease, Liability, Payments, Due Year Three
2028
Lessee, Operating Lease, Liability, Payments, Due Year Four
2029
Lessee, Operating Lease, Liability, Payments, Due
Total
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Discount factor
Depreciation, Depletion and Amortization
Depreciation expense
Tangible Asset Impairment Charges
Impairment of property, plant and equipment
Leasehold Improvements, Gross
Leasehold improvements
Machinery and Equipment, Gross
Machinery and equipment
Gross amount, as of the balance sheet date, of long-lived, depreciable assets used in the production process to produce goods and services and commonly used in offices and stores.
Furniture And Equipment Gross
Office equipment and furniture
Property, Plant and Equipment, Gross
Property, plant and equipment, gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated depreciation
Schedule of Finite-Lived Intangible Assets [Table]
Other Liabilities [Member]
Others
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets
Finite-Lived Intangible Asset, Useful Life
Estimated useful lives (in years)
Finite-Lived Intangible Assets, Gross
Cost of intangible assets
Purchase Price
Finite-Lived Intangible Assets, Remaining Amortization Period
Finite-lived intangible assets, remaining amortization period
Finite-Lived Intangible Assets, Accumulated Amortization
Accumulated Amortization
Accumulated amount of impairment of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Finite-Lived Intangible Assets, Accumulated Impairment
Impairment
Finite-Lived Intangible Assets, Net
Balance at the ending of the year
Balance at the beginning of the year
Carrying Amount
Finite-lived Intangible Assets Acquired
Addition
Amortization of Intangible Assets
Amortization expense
Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)
Foreign currency translation adjustment
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
2026
Finite-Lived Intangible Assets, Amortization Expense, Year Two
2027
Finite-Lived Intangible Assets, Amortization Expense, Year Three
2028
Finite-Lived Intangible Assets, Amortization Expense, Year Four
2029
Finite-Lived Intangible Assets, Amortization Expense, Year Five
2030
Finite-Lived Intangible Assets, Amortization Expense, after Year Five
2031 and thereafter
Other Employee-related Liabilities, Current
Payroll and welfare payable
The amount of current portion of grants related to land use right.
Grants Related to Land use Right, Current
Grants related to land use right
The amount of current portion of clinical study service payable as at the end of the reporting period.
Clinical Study Service Payable, Current
Payable to clinical study service
Accrued Professional Fees, Current
Payable to professional service
The amount of current portion of sales and marketing services payable as at the end of the reporting period.
Sales and Marketing Services Payable, Current
Payable to sales and marketing services
Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) loan principal payable (c) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Interest Loan Principal And Dividends Payable Current
Dividends and interest payable to Wuxi LP, current (Note 11)
Other Liabilities, Current
Others
The amount of noncurrent portion of Profit-sharing liability.
Profit-sharing Liability Non current
Profit-sharing liability to Juventas
Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the non-current portion of the liabilities (due within more than 12 month, or the operating cycle if longer).
Interest And Dividends Payable Non Current
Dividends and interest payable to Wuxi LP, non current (Note 11)
Line of Credit Facility [Table]
Lender Name [Axis]
Line of Credit Facility, Lender [Domain]
Represents information pertaining to Bank of Nanjing.
Bank of Nanjing [Member]
Bank of Nanjing
Represents information pertaining to bank of communications.
Bank of Communications [Member]
Bank of Communications
Line of Credit Facility [Line Items]
Short term borrowings
Line of Credit Facility, Maximum Borrowing Capacity
Maximum borrowing
Schedule of information pertaining to grants receivable or received by the company.
Grants, Disclosure [Table]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Grants, Disclosure [Line Items]
Grants
This information is pertaining to the amount of grants eligible.
Grants Eligible
Amount of grants eligible
Other Income
Other income
Noncontrolling Interest [Table]
Represents the information pertaining to WUXI LP.
WUXI LP [Member]
WUXI LP
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Option Indexed to Issuer's Equity, Type [Axis]
Option Indexed to Issuer's Equity, Type [Domain]
Call Option [Member]
Call option
Put Option [Member]
Put option
Noncontrolling Interest [Line Items]
Noncontrolling Interest
Represent the investment commitment.
Investment Commitment
Investment commitment
Initial cash investment.
Initial Cash Investment
Initial cash investment
Represent the selected and as to be transferred.
Selected Andas To Be Transferred
Value of transfer of selected ANDAs
Payments to Acquire Investments
Payments to acquire investments
The amount of reduction in registered capital.
Reduction in Registered Capital
Reduction in capital
The amount of investment return payable in installments.
Investment Return Payable in Installments
Investment return in installments
Number of installments in which carrying value as of the balance sheet date of investment return payable as a dividend.
Investment Return Payable as A Dividend, Number of Installments
Number of installments in which investment is paid
Carrying value as of the balance sheet date of investment return payable as a dividend.
Investment Return Payable as A Dividend, Year One
Dividend payable, installment one
Carrying value as of the balance sheet date of investment return payable as a dividend of year two.
Investment Return Payable as A Dividend, Year Two
Dividend payable, installment two
Carrying value as of the balance sheet date of investment return payable as a dividend of year three.
Investment Return Payable as A Dividend, Year Three
Dividend payable, installment three
Carrying value as of the balance sheet date of investment return payable as a dividend of year four.
Investment Return Payable as A Dividend, Year Four
Dividend payable, installment four
Call option purchase investment period.
Call Option To Purchase Investment Period
Call option purchase investment period
Number of guarantee agreements.
Number of Guarantee Agreements
Number of guarantee agreements
Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount
Balance at end of year
Balance at beginning of year
Amount of Accretion of Redeemable Non Controlling Interest.
Accretion of Redeemable Non Controlling Interest
Accretion of redeemable noncontrolling interest
Adjustments to noncontrolling interests which are redeemable by the (parent) entity foreign currency translation adjustments.
Redeemable Noncontrolling Interest, Equity, Common, Foreign Currency Translation Adjustments
Foreign currency translation adjustment
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests
Redemption of Wuxi NCI
Securities Purchase Agreements [Abstract]
Stock, Class of Stock [Table]
Represents information pertaining to 2024 At-the-Market offering.
At The Market Offering 2024 [Member]
Market offering 2024
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Represents information pertaining to pre-funded warrants.
Prefunded Warrants [Member]
Prefunded warrants
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount
Stock repurchased authorized amount
Stock Repurchase Program, Number of Shares Authorized to be Repurchased
Stock repurchase authorized (in shares)
Stock Repurchased During Period, Shares
Repurchase of common stock (in shares)
Stock Repurchased During Period, Value
Repurchase of common stock
Excess Stock, Shares Authorized
Additional shares of common stock purchase
Shares Issued, Price Per Share
Share issued price
Maximum aggregate offering price of stock agreed to be sold in a stock sale transaction.
Sale Of Stock, Maximum Aggregate Offering Price
Offer or sale of Aggregate price
The cash outflow for cost incurred as sales commission associated with underwriting activities.
Payments For Underwriter's Sales Commissions
Underwriter's sales commission
Per share or per unit amount of equity securities issued, net of exercise price of warrants.
Shares Issued Price Per Share, Net Of Exercise Price Of Warrants
Exercise price per share
Issuance price
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrants outstanding, exercise price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Warrants
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Ending balance
Beginning balance
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Issued
The number of grants made during the period on other than stock (or unit) option plans.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise In Period
Exercised
The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable during the reporting period
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable
Exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Ending balance
Beginning balance
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Issued
Weighted average exercise price of equity instruments other than options.
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other than Options, Exercised In Period, Weighted Average Exercise Price
Exercised
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price
Exercisable
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities excluded from computation of earnings per share amount (in shares)
Class of Warrant or Right, Outstanding
Warrants outstanding (in shares)
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Numerator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Denominator:
Defined Benefit Plan, Plan Assets, Contributions by Employer
Employer contributions
Defined Contribution Plan, Cost
Defined contribution plan expenses
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Research and Development Expense [Member]
Research and development
Selling and Marketing Expense [Member]
Sales and marketing
General and Administrative Expense [Member]
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award
The weighted average modification-date fair value of modified options during the reporting period as calculated by applying the disclosed option pricing methodology.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Plan Modification In Period, Weighted Average Modification Date Fair Value
Weighted average modification date fair value
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk free interest rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Weighted average expected option life (in years)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Range of expected volatility, Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Range of expected volatility, Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Range of risk free interest rate, Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Range of risk free interest rate, Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average fair value of share options
Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]
Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]
Information related to performance-based options.
Performance Based Option [Member]
Performance Based Option
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Ending Balance (in shares)
Beginning Balance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Granted (in shares)
Granted shares of common stock
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Expired (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Vested and expected to vest (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Ending Balance (in dollars per share)
Beginning balance (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted (in dollars per share)
Common stock exercise price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Expired (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Vested and expected to vest (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term In Years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Vested and expected to vest - Weighted Average Remaining Contractual Term In Years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Exercisable - Weighted Average Remaining Contractual Term In Years
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Range One [Member]
$1.26 - $1.93
Range Two [Member]
$2.31 - $2.69
Range Three [Member]
$3.59 - $5.20
Range Four [Member]
$5.78 - $6.89
Range Five [Member]
$42.70
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit
Range of Exercise Prices Lower Range Limit (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit
Range of Exercise Prices Upper Range Limit (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options
Options Outstanding, Number Outstanding (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term
Options Outstanding, Weighted Average Remaining Contractual Life (in years)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Options Outstanding, Weighted Average Exercise Price (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options
Options Exercisable, Number Exercisable (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price
Options Exercisable, Weighted Average Exercise Price (in dollars per share)
Plan Name [Axis]
Plan Name [Domain]
Information related to the 2011 Long-Term Incentive Plan.
Long Term Incentive Plan 2011 [Member]
Long Term Incentive Plan 2011
Information related to the 2021 Long-Term Incentive Plan.
Long Term Incentive Plan 2021 [Member]
Long Term Incentive Plan 2021
Represents information pertaining to 2024 long-term incentive plan.
Long-Term Incentive Plan 2024 [Member]
Long Term Incentive Plan 2024
Represents information pertaining to time based stock options.
Time Based Stock Options [Member]
Time Based Stock Options
The amount of estimated share-based compensation expense.
Estimated Share-Based Compensation Expense
Estimated share-based compensation expense
Share-Based Payment Arrangement, Plan Modification, Incremental Cost
Share-Based Payment Arrangement, Plan Modification, Incremental Cost
Share-Based Payment Arrangement, Expense
Share-Based Payment Arrangement, Expense
The amount of share-based compensation expense to be paid over the remaining vesting period.
Share-based Compensation Expense To Be Paid Over The Remaining Vesting Period
Recognized through the remaining vesting period of each of the original unvested awards
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Shares that are available for grants and awards
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Shares available for grants
Represents the expire date of stock other than option granted under share based compensation
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms
It represents the amount share-based payment cash received from stock option exercises.
Share Based Payment Cash Received from Stock Option Exercises
Share Based Payment Cash Received from Stock Option Exercises
Total unrecognized compensation cost expected to be recognized over a weighted-average period.
Total Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period
Total unrecognized compensation expense related to non-vested share options
Unrecognized compensation cost is expected to be recognized over a weighted-average period.
Unrecognized Share Based Compensation Cost Expected To Recognize Over Weighted Average Period
Unrecognized compensation cost is expected to be recognized over a weighted-average period (in years)
Income (Loss) from Continuing Operations before Income Taxes, Domestic
United States
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Mainland China and Hong Kong
Deferred income tax assets and liabilities
Components of Deferred Tax Assets [Abstract]
Deferred income tax assets:
Deferred Tax Assets, Operating Loss Carryforwards
Net operating loss carryforwards
Deferred Tax Assets, Tax Credit Carryforwards, Research
Research and development credit carryforwards
Deferred Tax Assets, Goodwill and Intangible Assets
Intangible assets
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Share-based compensation
Deferred Tax Assets, Investments
Change in fair value of investments
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized R&D amortization
Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Amortization
Capitalized R&D amortization
Amount before allocation of valuation allowances of deferred tax assets, lease liabilities.
Deferred Tax Assets, Lease Liabilities
Lease liability
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from impairment loss of long-term investments
Deferred Tax Assets, Tax Deferred Expense, Impairment Loss Of Long-term Investments
Impairment loss of long-term investments
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from write down of inventory
Deferred Tax Assets, Tax Deferred Expense, Inventory Write Down
Write down of inventories
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued interest expense.
Deferred Tax Assets, Accrued Interest Expense
Accrued interest expense
Deferred Tax Assets, Other
Others
Deferred Tax Assets, Valuation Allowance
Valuation allowance for deferred income tax assets
Ending Balance
Beginning Balance
Deferred Tax Assets, Net of Valuation Allowance
Net deferred income tax assets
Components of Deferred Tax Liabilities [Abstract]
Deferred income tax liabilities:
Amount of deferred tax liability attributable to taxable temporary differences from deferred tax liabilities, right of use assets.
Deferred Tax Liabilities, Right Of Use Assets
Right of use asset
Deferred Tax Liabilities, Other
Others
Deferred Tax Liabilities, Net
Net deferred income tax liabilities
Effective Income Tax Rate Reconciliation [Table]
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Domestic Tax Authority [Member]
Domestic Tax Authority
Foreign Tax Authority [Member]
Foreign Tax Authority
Effective Income Tax Rate Reconciliation [Line Items]
INCOME TAXES
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Tax benefit at statutory federal rate
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of tax attributes, such as net operating losses or tax credit carryforwards.
Effective Income Tax Rate Reconciliation, Attribute Expiration, Amount
Attribute expiration
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Nondeductible expenses
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Deduction, Amount
Research and development bonus deduction
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
Tax rate differential
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount
Tax shortfalls from share options
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Others
Tax Jurisdiction of Domicile [Extensible Enumeration]
Tax Jurisdiction of Domicile [Extensible Enumeration]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Percent
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Federal statutory rate (as a percent)
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of tax attributes, such as net operating losses or tax credit carryforwards.
Effective Income Tax Rate Reconciliation, Attribute Expiration, Percent
Attribute expiration
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Nondeductible expenses
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Deduction, Percent
Research and development bonus deduction
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Tax rate differential
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent
Tax shortfalls from share options
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Others
Effective Income Tax Rate Reconciliation, Percent
Effective tax rate
Amount before allocation of valuation allowances of increase decrease in deferred tax assets.
Increase Decrease In Deferred Tax Assets
Additions
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Decrease from attribute expiration
Amount before allocation of valuation allowances of deferred tax assets foreign currency translation adjustment.
Deferred Tax Assets Foreign Currency Translation Adjustment
Foreign currency translation adjustment
Unrecognized Tax Benefits
Ending Balance
Beginning Balance
Unrecognized tax benefits
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Reductions for tax positions of prior periods
Net reduction of unrecognized tax benefits
Income Tax Contingency [Table]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name [Domain]
Research Tax Credit Carryforward [Member]
Research Tax Credit Carryforward
Income Tax Contingency [Line Items]
Income Tax Contingency
Percentage of valuation allowance recognized.
Percentage of Valuation Allowance Recognized
Percentage of valuation allowance recognized
Deferred Tax Assets, Net
Net deferred tax assets
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Income tax, interest or penalties
Operating Loss Carryforwards
Operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration
Operating loss carryforwards not subject to expiration
Tax Credit Carryforward, Amount
Operating loss carryforwards, tax
Period in which tax credit carryforwards expire in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.
Tax Credit Carryforward, Expiration Period
Expiration period for unused tax carryforwards
Amount of underpayment of taxes leads to extension of statue of limitation.
Underpayment of Taxes, Statue of Limitation Extended term
Underpayment of taxes, statue of limitation extended term
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Fair Value, Inputs, Level 2 [Member]
Level 2
Fair Value, Inputs, Level 3 [Member]
Level 3
Fair Value, Nonrecurring [Member]
Non-recurring
Debt Securities, Available-for-Sale
Convertible note
The amount of investments fair value disclosure of equity securities in ordinary shares.
Investments, Fair Value Disclosure, Equity Securities in Ordinary Shares
Investment in ordinary shares
Amount of Investments fair value disclosure warrants measured at fair value through profit and loss.
Investments Fair Value Disclosure Warrants Measured At Fair Value Through Profit And Loss
Investment in warrants - Designated as investment measured at FVTPL
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure
Intangible assets, fair value
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Measurement Inputs and Valuation Techniques
Debt Securities, Available-for-Sale, Valuation Technique [Extensible Enumeration]
Debt Securities, Available-for-Sale, Measurement Input [Extensible Enumeration]
Debt Securities, Available-for-Sale, Measurement Input
Average/Median
The amount of non-financial assets measured at fair value.
Non-Financial Assets, Fair Value Disclosure
Non-financial assets, measured at fair value
The fair value carrying amount.
Fair Value Carrying Amount
Carrying amount
Impairment of Intangible Assets (Excluding Goodwill)
Impairment of intangible assets
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]
Debt Securities, Available-for-sale, Noncurrent
Available-for-sale debt securities
Schedule of Related Party Transactions, by Related Party [Table]
Represents information pertaining to ETP Global III Fund LP.
ETP Global III Fund LP [Member]
ETP Global III
Convertible Debt Securities [Member]
Convertible Note
Represents information pertaining to Tranche One.
Convertible Notes Tranche One [Member]
Tranche One
Represents information pertaining to Tranche Two.
Convertible Notes Tranche Two [Member]
Tranche Two
Represents information pertaining to Tranche Three.
Convertible Notes Tranche Three [Member]
Tranche Three
Represents information pertaining to Tranche Four.
Convertible Notes Tranche Four [Member]
Tranche Four
Related Party Transaction [Line Items]
RELATED PARTY TRANSACTIONS
Debt Instrument, Face Amount
Face amount
Aggregate Principal Amount
Represents the number of consecutive trading days immediately preceding the the maturity date regarding the volume weight average closing price to compute conversion price.
Debt Instrument, Convertible, Volume Weighted Average Closing Price, Consecutive Trading Days Preceding Maturity Date
Number of consecutive trading days
Represents information pertaining to Huiying Memorial Foundation.
Huiying Memorial Foundation [Member]
Huiying Memorial Foundation
Represents information pertaining to Panacea Venture Healthcare Fund II, L.P.
Panacea Venture Healthcare Fund II LP [Member]
Panacea Venture Healthcare Fund II, L.P.
Proceeds from Issuance of Common Stock
Gross proceeds from the offering
Person with designation of chairman and chief executive officer.
Chairman And Chief Executive Officer [Member]
Chairman and Chief Executive Officer
Represents information pertaining to HE family GRAT, a grantor retained annuity trust for the benefit of CEO's family members.
He Family GRAT [Member]
He Family GRAT
Represents information pertaining to Human Longevity Inc.
Human Longevity Inc [Member]
Human Longevity Inc
Related Party Transaction [Axis]
Related Party Transaction [Domain]
The cash inflow from certain labor cost and certain preclinical and clinical services
Proceeds from Reimbursement Of Labor, Preclinical And Clinal Expense
Reimbursement of labor, preclinical and clinal expense
Proceeds from Collection of Other Receivables
Other receivables
The rate of interest that was being paid on certain investments calculated from the date of investment through the date of payment of aggregate equity consideration.
Interest Rate On Equity Consideration Payable
Interest Rate
The amount of service fee for each month for usage of office facility.
Service Fee Per Month
service charge
Other Commitments [Table]
Represents the information pertaining to Acrotech Biopharma L.L.C.
Acrotech Biopharma L.L.C. [Member]
Acrotech Biopharma LLC
Other Commitments [Line Items]
COMMITMENTS AND CONTINGENCIES
The number of milestones achieved.
Number Milestones Achieved
Number of milestones achieved
The total consideration paid over the term of the agreement.
Total Milestone Consideration
Total consideration paid over term of agreement
The number of milestone payments yet to be paid.
Number Milestones Payments Outstanding
Number of milestone payments yet to be paid
Restricted Investments
Restricted net assets
Subsequent Event [Table]
Subsequent Event [Line Items]
Subsequent Events
Condensed Balance Sheet Statement [Table]
Consolidated Entities [Axis]
Consolidated Entities [Domain]
Parent Company [Member]
Parent Company
Condensed Balance Sheet Statements, Captions [Line Items]
Condensed Balance Sheet Statements, Captions
The amount of intercompany receivables as of the balance sheet date.
Intercompany Receivables
Intercompany receivables
The amount of investments in subsidiaries as at the end of the reporting period.
Investment in Subsidiaries
Investment in subsidiaries
The amount of intercompany payables, payable within one year or the normal operating cycle, if longer.
Intercompany Payables, Current
Intercompany payables
Amount of provision for excess loss in subsidiaries.
Provision For Excess Loss In Subsidiaries
Provision of excess loss in subsidiaries
Condensed Income Statement [Table]
Condensed Income Statements, Captions [Line Items]
Condensed Income Statements, Captions
The amount of operating expenses from intercompany transactions during the reporting period.
Intercompany Operating Expenses
Intercompany expenses
Other Cost and Expense, Operating
Other operating expenses
Income (Loss) from Subsidiaries, before Tax
Share of loss of subsidiaries
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Loss before income tax expense
Condensed Cash Flow Statement [Table]
Condensed Cash Flow Statements, Captions [Line Items]
Condensed Cash Flow Statements, Captions
Payments to Acquire Additional Interest in Subsidiaries
Investment in subsidiaries